Arlington capital partners announces the acquisition of avs bio

Washington--( business wire )--arlington capital partners (“arlington”), a washington, dc-area private equity firm, announced today it has acquired charles river laboratories' (nyse:crl) avian vaccine services business to form a new company, avs bio (the “company”). the company will operate independently as a standalone platform for arlington that will serve the biologic manufacturing and bioprocessing markets.
CRL Ratings Summary
CRL Quant Ranking